These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38647051)

  • 21. Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.
    Royston L; Papanicolaou GA; Neofytos D
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.
    Winston DJ; Saliba F; Blumberg E; Abouljoud M; Garcia-Diaz JB; Goss JA; Clough L; Avery R; Limaye AP; Ericzon BG; Navasa M; Troisi RI; Chen H; Villano SA; Uknis ME;
    Am J Transplant; 2012 Nov; 12(11):3021-30. PubMed ID: 22947426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maribavir: a novel antiviral agent with activity against cytomegalovirus.
    Trofe J; Pote L; Wade E; Blumberg E; Bloom RD
    Ann Pharmacother; 2008 Oct; 42(10):1447-57. PubMed ID: 18698013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States.
    Blumberg EA; Hauser IA; Stanisic S; Mueller E; Berenson K; Gahlemann CG; Humar A; Jardine AG
    Transplantation; 2010 Dec; 90(12):1420-6. PubMed ID: 21063245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients.
    Puttarajappa CM; Hariharan S; Smith KJ
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):290-298. PubMed ID: 29025787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Novelties for the management of cytomegalovirus after kidney transplantation].
    Kamar N; Marion O; Del Bello A
    Nephrol Ther; 2024 Aug; 20(4):269-276. PubMed ID: 39129511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maribavir failure in refractory cytomegalovirus infection in a lung transplant patient on extracorporeal membrane oxygenation.
    Kroll C; Non L; Ince D
    Transpl Infect Dis; 2024 Jun; 26(3):e14275. PubMed ID: 38584587
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.
    Chou S; Wu J; Song K; Bo T
    Antiviral Res; 2019 Dec; 172():104616. PubMed ID: 31568799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR
    World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
    Papanicolaou GA; Avery RK; Cordonnier C; Duarte RF; Haider S; Maertens J; Peggs KS; Solano C; Young JH; Fournier M; Murray RA; Wu J; Winston DJ;
    Clin Infect Dis; 2024 Mar; 78(3):562-572. PubMed ID: 38036487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient.
    Fisher JE; Mulieri K; Finch E; Ericson JE
    J Pediatr Hematol Oncol; 2024 Apr; 46(3):e244-e247. PubMed ID: 38447094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir.
    Strasfeld L; Lee I; Tatarowicz W; Villano S; Chou S
    J Infect Dis; 2010 Jul; 202(1):104-8. PubMed ID: 20504236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus.
    Sun K; Hayes S; Farrell C; Song IH
    CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):719-723. PubMed ID: 36789522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients.
    Imlay HN; Kaul DR
    Clin Infect Dis; 2021 Jul; 73(1):156-160. PubMed ID: 33197929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ; Razonable RR
    Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro studies of the impact of maribavir on CMV-specific cellular immune responses.
    Stachel D; Stevens-Ayers T; Boeckh M
    J Clin Virol; 2016 Feb; 75():53-9. PubMed ID: 26780109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective.
    Alsumali A; Chemaly RF; Graham J; Jiang Y; Merchant S; Miles L; Schelfhout J; Yang J; Tang Y
    J Med Virol; 2021 Jun; 93(6):3786-3794. PubMed ID: 32844453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation].
    Kawalec P; Holko P; Szkultecka-Debek M; Paszulewicz A; Boratyńska M; Głyda M; Ignacak E; Maks J; Russel-Szymczyk M; Kaweczyńska-Lasoń A
    Pol Merkur Lekarski; 2013 Jun; 34(204):332-8. PubMed ID: 23882930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient.
    Pearce H; Montgomery EK; Sheerin N; Ellam H
    Transpl Int; 2024; 37():11985. PubMed ID: 38314399
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.